A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

Summary

The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.

Timeline

Start

2026-02-20

Primary completion

2028-05-28

Completion

2028-07-23

Drugs

Indications